Loading clinical trials...
Loading clinical trials...
The purpose of this study is to continue to measure the safety, tolerability, and durability of treatment effect in subjects with Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), or Idiopathic Hypers...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Alkermes, Inc.
NCT07299097 · Narcolepsy Type 1, Narcolepsy Type 2
NCT07363720 · Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy
NCT05816382 · Narcolepsy Type 1
NCT06952699 · Narcolepsy Type 2
NCT06292598 · Narcolepsy Type 1, Bacterial Translocation
Alkermes Investigator Site
Phoenix, Arizona
Alkermes Investigational Site
Little Rock, Arkansas
Alkermes Investigational Site
Los Angeles, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions